Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Sold by Logos Global Management LP

Logos Global Management LP cut its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 24.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,700,000 shares of the company’s stock after selling 1,550,000 shares during the quarter. Logos Global Management LP’s holdings in Lineage Cell Therapeutics were worth $4,687,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of LCTX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after purchasing an additional 70,418 shares during the last quarter. Comerica Bank boosted its stake in shares of Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after acquiring an additional 250,000 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Lineage Cell Therapeutics during the 1st quarter worth about $30,000. DCF Advisers LLC boosted its stake in Lineage Cell Therapeutics by 14.5% during the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after purchasing an additional 12,000 shares during the period. Finally, XTX Topco Ltd bought a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $61,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Craig Hallum assumed coverage on Lineage Cell Therapeutics in a report on Tuesday, August 20th. They set a “buy” rating and a $4.00 price objective on the stock.

Lineage Cell Therapeutics Price Performance

LCTX stock opened at $0.94 on Tuesday. Lineage Cell Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $1.61. The stock has a market cap of $178.04 million, a PE ratio of -6.73 and a beta of 1.26.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative return on equity of 36.30% and a negative net margin of 391.00%. As a group, equities research analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.